Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.

Executive Summary

Members of FDA's Anti-Infective Drugs Advisory Committee questioned the usefulness of approving antibiotics specifically for pathogen-resistant indications at a March 24 meeting held to discuss the safety and efficacy of Pharmacia & Upjohn's oxazolidinone antibiotic Zyvox (linezolid)
Advertisement

Related Content

Zyvox Phase IV Studies May Support Penicillin-Resistant Indications
Zyvox Phase IV Studies May Support Penicillin-Resistant Indications
Zyvox Comparison To Synercid In VRE Infections Recommended By FDA Cmte.
Zyvox Comparison To Synercid In VRE Infections Recommended By FDA Cmte.
Advertisement
UsernamePublicRestriction

Register

PS035823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel